LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGING Bottle carton

1. NAME OF THE MEDICINAL PRODUCT

Lamivudine/Tenofovir Disoproxil Fumarate 300mg/300mg Tablets*

2. STATEMENT OF ACTIVE SUBSTANCE

Each film-coated tablet contains 300 mg lamivudine and 300mg tenofovir disoproxil fumarate (equivalent to 245 mg of tenofovir disoproxil or 136 mg of tenofovir).

3. LIST OF EXCIPIENTS

Contains lactose. See patient information leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

30 film-coated tablets 100 film-coated tablets

5. METHOD AND ROUTE OF ADMINISTRATION

Oral use Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

^{*} Trade names are not prequalified by WHO. This is under local DRA responsibility. Throughout this WHOPAR the proprietary name is given as an example only.

8. EXPIRY DATE

EXP {MM/YYYY}

9. SPECIAL STORAGE CONDITIONS

Do not store above 30°C. Store in the original container. Protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE SUPPLIER

Mylan Laboratories Limited Plot No. 564/A/22, Road No.92, Jubilee Hills Hyderabad - 500034, Telangana, India Tel No: +91 40 39258109 Email: <u>imtiyaz.basade@mylan.in</u>

12. WHO REFERENCE NUMBER (PREQUALIFICATION PROGRAMME)

HA414

13. MANUFACTURER'S BATCH NUMBER

<Batch> {number}

14. (ADVICE ON) GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING Bottle label

1. NAME OF THE MEDICINAL PRODUCT

Lamivudine/Tenofovir Disoproxil Fumarate 300mg/300mg Tablets

2. STATEMENT OF ACTIVE SUBSTANCE

Each film-coated tablet contains 300 mg lamivudine and 300mg tenofovir disoproxil fumarate (equivalent to 245 mg of tenofovir disoproxil or 136 mg of tenofovir).

3. LIST OF EXCIPIENTS

Contains lactose. See patient information leaflet for further information.

4. PHARMACEUTICAL FORM AND CONTENTS

30 film-coated tablets 100 film-coated tablets

5. METHOD AND ROUTE OF ADMINISTRATION

Oral use Read the package leaflet before use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP {MM/YYYY}

Lamivudine/Tenofovir Disoproxil Fumarate 300mg/300 mg Tablets (Mylan Lab. Ltd), HA414

9. SPECIAL STORAGE CONDITIONS

Do not store above 30°C. Store in the original container. Protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE SUPPLIER

Mylan Laboratories Limited Plot No. 564/A/22, Road No.92, Jubilee Hills Hyderabad - 500034, Telangana, India Tel No: +91 40 39258109 Email: <u>imtiyaz.basade@mylan.in</u>

12. WHO REFERENCE NUMBER (PREQUALIFICATION PROGRAMME)

HA414

13. MANUFACTURER'S BATCH NUMBER

<Batch> {number}

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE